Analysis – Page 2 – Goldea Capital

Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting

Written by Customer Service on March 28, 2026. Posted in Public Companies.

Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621’s compelling oral profile Parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late-2027, respectively WATERTOWN, Mass., March 28, 2026 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the positive results from the BroADen Phase 1b atopic dermatitis (AD) clinical trial of KT-621, its first-in-class, oral STAT6 degrader, were featured in a late-breaking oral presentation at the American Academy of Dermatology (AAD) Annual Meeting. The meeting is being held March 27-31, 2026, in Denver, CO. “We’re...

Press Release: AAD: new results from Sanofi’s amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session

Written by Customer Service on March 28, 2026. Posted in Public Companies.

AAD: new results from Sanofi’s amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research sessionAcross the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed either Q4W or Q12W, showed progressively increasing efficacy, with no evidence of plateau at Week 24 across endpoints Data reinforce potential for Q12W dosing from the startParis, March 28, 2026. Positive results from three phase 3 studies of amlitelimab, a fully human non-T cell depleting monoclonal antibody that selectively targets OX40-ligand (OX40L), in moderate-to-severe atopic dermatitis (AD) as a monotherapy and in combination with topical therapies, showed improvements in skin clearance and disease severity with amlitelimab treatment compared to placebo in patients aged 12 years and older. The studies, COAST 1 (clinical study...

Rocket Lab Successfully Launches 85th Mission and First Dedicated Launch for European Space Agency

Written by Customer Service on March 28, 2026. Posted in Public Companies.

Rocket Lab Electron Launch For European Space AgencyRocket Lab Electron Launch For European Space AgencyMAHIA, New Zealand, March 28, 2026 (GLOBE NEWSWIRE) — Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab” or the “Company”), a global leader in launch services and space systems, today successfully completed its first dedicated launch for the European Space Agency (ESA), demonstrating Electron’s key and growing role in supporting space agency missions with repeatable and reliable commercial launch services. The launch, named “Daughter Of The Stars”, lifted off from Rocket Lab Launch Complex 1 in New Zealand on March 28th at 10:14 pm NZT to successfully deliver ESA’s “Celeste” mission to orbit: the first two spacecraft of a satellite navigation demonstration mission in low Earth orbit at 510 km. ESA’s Celeste mission will...

Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology

Written by Customer Service on March 28, 2026. Posted in Public Companies.

Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology Halle (Saale) / Munich, Germany, March 28, 2026 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that new data analyses from the Company’s varoglutamstat Phase 2 program were presented at the World Congress of Nephrology (WCN) held in Yokohama, Japan, March 28-31, 2026. “We are very pleased with the opportunity to share our consistently compelling results with world leading experts in the kidney space at WCN, the International Society of Nephrology’s flagship event,” said Frank Weber,...

Osisko Development Reports Fourth Quarter and Year-End 2025 Results

Written by Customer Service on March 28, 2026. Posted in Earnings Releases And Operating Results.

(All dollar amounts are expressed in Canadian dollars, unless stated otherwise) HIGHLIGHTS Q4 2025 (at December 31, 2025)Financial: ~$422.3 million in cash and cash equivalents; sold 3,970 ounces of gold from small-scale mining activities at the Tintic Project Financing: Completed a private placement financing for ~$82.5 million in gross proceeds Cariboo Gold Project: Released new infill drill results from the ongoing program in the Lowhee Zone and commenced a multi-faceted surface exploration program targeting new discoveries; pre-construction activities continued to advance, including the water treatment plant, underground development waste rock storage facility, sediment control pond, site camp upgrade and other critical infrastructure Corporate: Announced sale of the San Antonio Gold Project; Appointed Scott Smith as VP, ExplorationSubsequent...

Miata Metals Announces Grant of Stock Options

Written by Customer Service on March 28, 2026. Posted in Public Companies.

VANCOUVER, British Columbia, March 27, 2026 (GLOBE NEWSWIRE) — Miata Metals Corp. (CSE: MMET) (FSE: 8NQ) (OTCQX: MMETF) (“Miata” or the “Company”) wishes to announce that its Board of Directors has approved a grant of an aggregate of 450,000 stock options (“Options”) to certain employees and consultants of the Company, in accordance with Miata’s Omnibus Incentive Equity Plan (the “Omnibus Plan”). The Options vest 50% at six months and 50% at twelve months and have a three-year term from the date of grant, at an exercise price of $0.50 per common share. All the foregoing Options are subject to the terms of the Omnibus Plan, the applicable grant agreement, and the requirements of the Canadian Securities Exchange (the “CSE”). The Options and the underlying shares are subject to a four month hold period in accordance with applicable...

Constellation Software Inc. Announces Mark Leonard’s Decision to not Stand for Re-Election to Board of Directors

Written by Customer Service on March 27, 2026. Posted in Public Companies.

TORONTO, March 27, 2026 (GLOBE NEWSWIRE) — Constellation Software Inc. (TSX:CSU) (“Constellation”) announced today that Mark Leonard, the founder and former President of Constellation, will not stand for re-election to the Board of Directors. His current term will conclude following Constellation’s annual meeting of shareholders on May 15, 2026. Mr. Leonard will continue to serve as an advisor to Constellation, with a particular focus on supporting the company’s Permanent Engaged Minority Shareholder (“PEMS”) strategy—an initiative centered on selective, long-term, and engaged minority investments that complement Constellation’s longstanding acquisition model. Mark Miller, President of Constellation, stated: “Over more than three decades, Mark built Constellation into one of the world’s most distinctive and successful software companies....

Fusion Fuel Highlights Royal Uranium’s 2% NSR on Two Mineral Claims held by the Shea Creek Joint Venture, One of Canada’s Largest Undeveloped Uranium Projects in the Athabasca Basin

Written by Customer Service on March 27, 2026. Posted in Public Companies.

Part of a 16-uranium-royalty portfolio across the Athabasca Basin, Newfoundland, Colombia, and ArgentinaDublin, March 27, 2026 (GLOBE NEWSWIRE) — Fusion Fuel Green PLC (Nasdaq: HTOO) (“Fusion Fuel” or the “Company”), a leading provider of full-service energy engineering, advisory, and utility solutions, today highlighted information about its anticipated 2.0% Net Smelter Return (the “NSR”) royalty on two mineral claims – MC00040006 and MC0004007 – within a larger set of mineral claims held by the Shea Creek Joint Venture. The NSR is part of a portfolio of royalty rights that the Company anticipates will be acquired upon the closing of its previously announced agreement with Royal Uranium Inc. (“Royal Uranium”). The Shea Creek Joint Venture, in the Western Athabasca Basin area of northern Saskatchewan, Canada, is operated by...

HYTN Successfully Releases Cannabis Products in Germany and Accepts Reorder

Written by Customer Service on March 27, 2026. Posted in Public Companies.

VANCOUVER, British Columbia, March 27, 2026 (GLOBE NEWSWIRE) — HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or the “Company”), a pharmaceutical manufacturer specializing in products containing psychoactive and psychotropic compounds, including cannabis, is pleased to announce that wholesale cannabis products previously exported to Germany during the prior quarter have now been successfully released for sale in the German market. The release follows completion of required import, quality control, and market release procedures for Germany’s regulated medical cannabis market. Following this milestone, the Company has accepted a reorder for additional wholesale product. This milestone builds on HYTN’s previously announced strategic supply framework for Germany and further demonstrates the Company’s ability to...

American Hotel Income Properties REIT LP to Host Fourth Quarter 2025 Results Conference Call on March 31, 2026

Written by Customer Service on March 27, 2026. Posted in Public Companies.

VANCOUVER, British Columbia, March 27, 2026 (GLOBE NEWSWIRE) — American Hotel Income Properties REIT LP (“AHIP”, “the Company”) (TSX: HOT.UN, TSX: HOT.U, TSX: HOT.DB.V) announces today that it intends to release its financial results for the quarter ended December 31, 2025 after market close on Monday, March 30, 2026. Interested parties are invited to participate in the Company’s Q4 2025 results conference call, occurring on Tuesday, March 31, 2026, at 10:00 a.m. Pacific Time. During the call, Company executives will discuss AHIP’s financial results. To participate in the conference call, participants should register online here. A dial-in and unique PIN will be provided to join the call. Participants are requested to register a minimum of 15 minutes before the start of the call. An audio-only webcast of the call may be accessed...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals